Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study (TCIFCU)

27. april 2022 opdateret af: Bright Cloud International Corp

Home-based Virtual Reality System for the Treatment of Chemotherapy-related Cognitive Impairments

Develop a game-based upper-extremity motor and cognitive rehabilitation system using custom and adaptable virtual reality simulations.

Perform usability study on 2 elderly healthy volunteers and 2 breast cancer survivors with lasting cognitive impairments following chemotherapy, so to improve the product design. The usability evaluation will be done at NJ Bioscience Center (North Brunswick, NJ).

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

The study will generate data on ease of use of a system for subjects with stage II or stage III breast cancer survivors with lasting cognitive impairments subsequent to their first chemotherapy regimen. The usability component will uncover technical issues in its usability, as well as its rating on perceived usefulness. Data will also be collected on the ease of remote monitoring of the subjects by clinicians.

This portion of the study is intended to provide information pertaining to the usability of the experimental system for remote integrative (cognitive and motor) therapy of breast cancer survivors (Stage II or III) with lasting chemotherapy related cognitive impairment (CRCI) subsequent to first chemotherapy regimen, living in the community.

Specific aims are:

  1. testing of a added biosensors, new technology acceptance and ease of use at home by these individuals;
  2. a caregiver console and enhanced automatic session report that will allow remote monitoring of patient exercising and offline data processing and review.

Participants will each perform 4 usability evaluation sessions. At the end of each session participants will fill a custom evaluation form, using 5-point Likert scale scoring. At the end of the last session participants will also fill a USE standardized usability evaluation form.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New Jersey
      • North Brunswick, New Jersey, Forenede Stater, 08902
        • Bright Cloud Int'l Corp
      • North Brunswick, New Jersey, Forenede Stater, 08902
        • New Jersey Bioscience Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

The targeted subjects will be either breast cancer survivors, living in the community, without requiring transfers, or healthy, age-matched volunteers.

Beskrivelse

At NJ Bioscience Center Healthy Volunteers

  • Female
  • Age 20 to 65;
  • Good or corrected hearing;
  • Good or corrected vision;
  • No motor or cognitive impairments;
  • English speakers;
  • Those with low propensity for simulation sickness (as determined by the Simulation Sickness Questionnaire [Kennedy et al, 1993]).
  • Either healthy or having had stage II or stage III breast cancer;
  • Montreal Cognitive Assessment (MoCA) Score 10-25 indicating mild to moderate impairment [Chapman 2016] or 26-30 indicating normal cognition;

EXCLUSION CRITERIA

  • Male;
  • Female participants younger than 20 or older than 65;
  • High propensity for simulation sickness (as determined by Simulation Sickness Questionnaire screening);
  • Those with severe visual neglect or legally blind;
  • Those with severe hearing loss or deafness;
  • Those with uncontrolled hypertension (>190/100 mmHg);
  • Those with severe cognitive impairment (MoCA score<10);
  • Current diagnosis of moderate-severe depression (Beck Depression Inventory II score of 17-63);
  • a history of psychiatric illness, defined as serious psychiatric illness such as bipolar mood disorder and schizophrenia, or requiring psychiatric hospitalization.
  • a history of or current substance abuse;
  • a previous head injury resulting in loss of consciousness;
  • a prior diagnosis of neurological illness;
  • a current or prior diagnosis of brain cancer;
  • non-English speakers;
  • Those unable to reliable participate in pre-study assessment due to any reason;
  • Those with co-morbidities limiting arm and neck motor function (ex. lymphedema, chronic pain, severe arthritis);
  • Less than 1 month post first chemotherapy regimen or starting chemotherapy during 16 weeks post screening (as chemotherapy during study participation is a confounding factor);
  • Those with Stage IV (metastatic) breast cancer will be excluded;
  • Those presenting with multiple cancers, such as breast and arm bone cancer, or breast and brain cancer;
  • Those who are unwilling to allow a home inspection to ascertain Internet quality, determine best placement for the experimental or sham systems, for installation and removal of the systems and necessary repairs.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Usability study, healthy volunteers and those with cognitive impairments following chemotherapy

2 elderly healthy volunteers and 2 participants with lasting cognitive impairments following chemotherapy for breast cancer. All will perform evaluation of a computer-based experimental system. Participants will be

  • Female Either healthy or breast cancer survivor;
  • Age 20 to 65 years;
  • Have st least 12 years of formal education;
  • Be English speakers;

Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.

This usability evaluation will be conducted at the NJ Bioscience Center.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
USE questionnaire to assess the usability of a computerized system
Tidsramme: At the end of the 4th evaluation session (about 1 month from enrollment)

A standardized questionnaire to assess the usefulness, satisfaction and ease of use of the experimental system [Lund, 2001] when evaluated by study participants. The form consists of 30 questions, each rated on a 7-point Likert scale (1 worst 7 best). The score range for this form is 30 (min) to 210 (max).

Participants will also be able to comment in free form on aspects they liked most and least about the device.

At the end of the 4th evaluation session (about 1 month from enrollment)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Subjective rating questionnaire of the device and therapy
Tidsramme: At each of 4 evaluation sessions over 1 month from enrollment
Participants rate the usefulness, satisfaction issues, and ease of use of the experimental system and its therapeutic games, as well as ease of use of the Caregiver laptop. The Subjective Evaluation Form consists of questions, each rated on a 5-point Likert scale (1 worst to 5 best outcome).
At each of 4 evaluation sessions over 1 month from enrollment

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Simulation Sickness Questionnaire for participant
Tidsramme: Screening at consent (one time)
Form used at screening post-consent to determine a participant's propensity for simulation sickness [Kennedy et al.,1993]. The questionnaire asks participants to score 16 symptoms on a four point scale (0-3). Score range is 0 (best outcome - no likelihood of experiencing simulation sickness with the device) to 48 (worst outcome - certainty that the participant will experience severe simulation sickness).
Screening at consent (one time)
Cyber-sickness Susceptibility Questionnaire for participant
Tidsramme: Screening at consent (one time)
Form used at screening post-consent to determine a participant's propensity for simulation sickness [Freiwald et al., 2020]. The questionnaire asks participants 26 questions The first 13 questions ascertain the general heath and fitness of the subject, and have Yes/No answers The remaining 13 questions are score on a on a 5 point Likert scale, with five point Likert scales, referring to the frequency of each complaint's occurrence. These scales range from 0 to 4 with the labels "very rarely", "rarely", "occasionally", "frequently" and "very often".
Screening at consent (one time)
Montreal Cognitive Assessment (MoCA) to measure level of cognitive impairment
Tidsramme: Screening at consent (one time)
Used at screening post-consent to determine level of cognitive impairment [Nasreddine et al 2005] for participants. The form has a score range from 0 (worst) to 30 (best) - no cognitive impairments. For the participants with early Alzheimer's Disease the form will confirm the participant is in the score range of 19-25.
Screening at consent (one time)
Biosensor readings
Tidsramme: At each of 4 evaluation sessions over 1 month from enrollment
Custom biosensors will provide additional data which will be used to gauge levels of cognitive engagement with the tasks performed during the evaluation.
At each of 4 evaluation sessions over 1 month from enrollment
Game difficulty level
Tidsramme: At each of 4 evaluation sessions over 1 month from enrollment
Game difficulty level when performing a simulated game task using the experimental system. Levels are 1 (easiest) to 16 (hardest)
At each of 4 evaluation sessions over 1 month from enrollment
Heart rate
Tidsramme: Before and after each of 4 evaluation sessions over 1 month from enrollment
Heart rate (Pulse) measured with a medical meter at start and end of each usability evaluation session
Before and after each of 4 evaluation sessions over 1 month from enrollment
Blood pressure (systolic and diastolic)
Tidsramme: Before and after each of 4 evaluation sessions over 1 month from enrollment
Blood pressure (Systolic and diastolic) measured with a medical meter before and after each Usability evaluation session.
Before and after each of 4 evaluation sessions over 1 month from enrollment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Grigore C Burdea, PhD, Bright Cloud Int'l Corp

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. juni 2021

Primær færdiggørelse (Faktiske)

31. december 2021

Studieafslutning (Faktiske)

31. december 2021

Datoer for studieregistrering

Først indsendt

5. april 2021

Først indsendt, der opfyldte QC-kriterier

7. april 2021

Først opslået (Faktiske)

9. april 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. april 2022

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. april 2022

Sidst verificeret

1. april 2022

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

We will not disclose data on individual participants.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Usability study

3
Abonner